BriaCell Therapeutics Corp. (BCTX) Balance Sheet
BCTX balance sheet, FY2025
July 31, 2025 · U.S. dollars$29.8M assets = $5.9M liabilities + $23.8M equity
Both columns are drawn to the same scale: what BCTX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
BCTX financial health
Descriptive bands, not a rating. Fiscal FY2025.
BCTX balance sheet trends, FY2016–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $835,696FY2016 | $29.8MFY2025 | +48.7%/yr | |
| Total liabilities | $48,591FY2016 | $5.9MFY2025 | +70.6%/yr | |
| Shareholders’ equity | $787,105FY2016 | $24.6MFY2025 | +46.6%/yr | |
| Cash & short-term investments | $820,597FY2016 | $24.6MFY2025 | +45.9%/yr | |
| Total debt | $1.1MFY2018 | $32,476FY2021 | −69.3%/yr | |
| Net cash (debt) | $628,854FY2018 | $71.5MFY2021 | +$70.9M | |
| Working capital | $784,754FY2016 | $21.9MFY2025 | +$21.1M | |
| Current ratio | 17.15FY2016 | 5.01FY2025 | −12.14 | |
| Debt / equity | 1.19FY2018 | 0.00FY2021 | −1.18 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BCTX assets
BCTX liabilities and equity
BCTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
BCTX balance sheet
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $24.6M | $1.2M | $28.4M | $52.6M | $71.6M | $21,249 | $157,034 | $1.7M | $1.6M | $820,597 |
| Cash & equivalents | $14.4M | $1.2M | $28.4M | $52.6M | $71.6M | $21,249 | $157,034 | $720,259 | $1.0M | $131,576 |
| Short-term investments | $10.1M | $175 | — | — | — | — | $0 | $1.0M | $601,757 | $689,021 |
| Receivables | $776,542 | $1.9M | $958,562 | $30,911 | $15,714 | $22,515 | $2,816 | $14,563 | $5,601 | $2,669 |
| Inventory | $0 | −$1.4M | $5.7M | −$24,103 | $516,230 | $199,031 | $8,097 | $0 | $1 | $0 |
| Other current assets | $2.1M | $3.3M | $979,449 | $1.7M | $129,762 | $18,668 | $586 | $113,386 | $12,367 | $10,079 |
| Total current assets | $27.4M | $5.1M | $36.0M | $54.3M | $72.2M | $261,463 | $168,533 | $1.9M | $1.6M | $833,345 |
| Property, plant & equipment (net) | $408,099 | $538,872 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $449 |
| Goodwill & intangible assets | $253,705 | $277,360 | $287,228 | $295,404 | $306,954 | $260,866 | $276,121 | $274,733 | $1 | $1 |
| Long-term investments | $0 | $418,490 | $2 | $2 | $2 | $2 | $2 | $2 | $2 | $0 |
| Other non-current assets | $1.7M | $1.8M | $2 | $0 | $2 | $0 | $0 | $132,762 | $1,902 | $1,901 |
| Total assets | $29.8M | $8.2M | $36.3M | $54.6M | $72.5M | $522,331 | $444,656 | $2.3M | $1.6M | $835,696 |
| Liabilities | ||||||||||
| Accounts payable | $4.5M | $10.0M | $1.5M | $594,145 | $267,594 | $4,246 | $1,072 | $277,164 | $441,865 | — |
| Short-term debt | — | — | — | — | — | $249,799 | $322,526 | $1.1M | — | — |
| Deferred revenue | — | — | — | — | — | −$4,246 | −$1,072 | — | $506,908 | — |
| Total current liabilities | $5.5M | $10.4M | $2.4M | $1.2M | $695,862 | $4.0M | $1.1M | $1.3M | $885,904 | $48,591 |
| Long-term debt | $0 | $0 | $0 | $0 | $25,986 | $155,940 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $464,269 | $1.5M | $38.9M | $40.2M | $37.2M | $0 | $301,329 | $1.5M | $631,785 | $0 |
| Total liabilities | $5.9M | $11.9M | $41.3M | $41.4M | $38.0M | $4.1M | $1.1M | $1.3M | $885,904 | $48,591 |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $139.9M | $100.2M | $92.9M | $84.1M | $68.5M | $12.3M | $11.1M | $7.8M | $5.3M | $3.4M |
| Retained earnings (deficit) | −$153.7M | −$118.6M | −$107.7M | −$77.4M | −$36.4M | −$18.2M | −$14.7M | −$9.7M | −$6.7M | −$4.3M |
| Accumulated other comprehensive income | $38.4M | −$192,524 | −$185,215 | −$177,858 | −$173,322 | −$138,684 | −$101,176 | −$80,982 | −$57,908 | −$23,232 |
| Minority interest | — | −$302,522 | $0 | — | — | — | — | — | — | — |
| Total shareholders' equity | $24.6M | −$3.3M | −$5.0M | $13.2M | $34.6M | −$3.6M | −$688,665 | $945,016 | $750,232 | $787,105 |
| Key figures | ||||||||||
| Total debt | — | — | — | — | $32,476 | $249,799 | $322,526 | $1.1M | — | — |
| Net cash (debt) | — | — | — | — | $71.5M | −$228,550 | −$165,492 | $628,854 | — | — |
| Working capital | $21.9M | −$5.3M | $33.6M | $53.1M | $71.5M | −$3.7M | −$964,788 | $537,519 | $748,327 | $784,754 |
| Tangible book value | $24.3M | −$3.6M | −$5.3M | $13.0M | $34.3M | −$3.9M | −$964,786 | $670,283 | $750,231 | $787,104 |
| Book value per share | $13.05 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 1.9M | — | — | — | — | — | — | — | — | — |
| Current ratio | 5.01 | 0.49 | 14.96 | 45.00 | 103.81 | 0.07 | 0.15 | 1.40 | 1.84 | 17.15 |
| Quick ratio | 4.63 | 0.30 | 12.20 | 43.64 | 102.88 | 0.01 | 0.14 | 1.32 | 1.83 | 16.94 |
| Debt / equity | — | — | — | — | 0.00 | — | — | 1.19 | — | — |
| Equity / assets | 82.6% | −40.6% | −13.9% | 24.3% | 47.7% | −688.7% | −154.9% | 41.4% | 45.9% | 94.2% |
| Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | Jul '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $22.8M | $29.9M | $10.2M | $24.6M | $17.2M | $7.4M | $8.1M | $1.2M | $1.3M | $8.4M | $18.8M | $28.4M |
| Cash & equivalents | $6.9M | $29.9M | $2.7M | $14.4M | $17.2M | $7.4M | $8.1M | $1.2M | $1.3M | $8.4M | $18.8M | $28.4M |
| Short-term investments | $15.9M | $0 | $7.5M | $10.1M | — | — | — | $175 | — | — | — | — |
| Receivables | $2.6M | $3.1M | $1.2M | $776,542 | $3.2M | $3.2M | $3.4M | $1.9M | $20,816 | $40,519 | $29,434 | $958,562 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | −$1.4M | −$1.7M | $5.5M | $4.7M | $5.7M |
| Other current assets | $0 | $0 | $0 | $2.1M | $0 | $1 | $1 | $3.3M | $8.0M | $1.9M | $1.8M | $979,449 |
| Total current assets | $25.4M | $32.2M | $11.3M | $27.4M | $20.4M | $10.6M | $11.4M | $5.1M | $7.6M | $15.8M | $25.3M | $36.0M |
| Property, plant & equipment (net) | $348,997 | $251,141 | $273,980 | $408,099 | $441,639 | $504,772 | $508,547 | $538,872 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $173,072 | $176,889 | $180,707 | $253,705 | $188,343 | $280,021 | $272,869 | $277,360 | $280,325 | $485,974 | $503,910 | $287,228 |
| Long-term investments | $750,982 | $582,455 | $554,448 | $0 | $496,653 | $454,391 | $421,975 | $418,490 | $469,660 | $281,657 | $2 | $2 |
| Other non-current assets | $405,085 | $405,085 | $717,508 | $1.7M | $1.9M | $2.0M | $1.9M | $1.8M | $170,065 | $0 | $0 | $2 |
| Total assets | $27.1M | $33.6M | $13.1M | $29.8M | $23.5M | $13.8M | $14.5M | $8.2M | $8.5M | $16.4M | $25.6M | $36.3M |
| Liabilities | ||||||||||||
| Accounts payable | $2.2M | $1.9M | $2.1M | $4.5M | $4.5M | $7.4M | $5.9M | $10.0M | $8.8M | $5.0M | $596,546 | $1.5M |
| Total current liabilities | $3.6M | $3.2M | $3.3M | $5.5M | $6.0M | $7.7M | $6.9M | $10.4M | $9.2M | $5.3M | $1.4M | $2.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $71,854 | $195,096 | $406,873 | $464,269 | $1.0M | $1.3M | $2.4M | $1.5M | $7.8M | $22.3M | $20.7M | $38.9M |
| Total liabilities | $3.7M | $3.4M | $3.7M | $5.9M | $7.0M | $9.0M | $9.3M | $11.9M | $17.0M | $27.6M | $22.1M | $41.3M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $117.1M | $116.4M | $101.7M | $139.9M | $129.9M | $125.9M | $114.2M | $100.2M | $95.1M | $93.5M | $95.7M | $92.9M |
| Retained earnings (deficit) | −$134.3M | −$126.4M | −$120.0M | −$153.7M | −$143.2M | −$143.8M | −$127.0M | −$118.6M | −$115.1M | −$115.5M | −$102.6M | −$107.7M |
| Accumulated other comprehensive income | −$138,684 | $40.7M | −$138,684 | $38.4M | −$191,605 | −$204,392 | −$193,048 | −$192,524 | −$189,515 | −$186,414 | −$190,662 | −$185,215 |
| Minority interest | −$649,099 | −$702,631 | −$627,558 | — | −$474,058 | −$376,031 | — | — | — | — | — | — |
| Total shareholders' equity | $24.1M | $30.7M | $10.0M | $24.6M | $17.2M | $5.3M | $5.6M | −$3.3M | −$8.2M | −$10.9M | $3.7M | −$5.0M |
| Key figures | ||||||||||||
| Working capital | $21.8M | $29.0M | $8.0M | $21.9M | $14.4M | $2.8M | $4.5M | −$5.3M | −$1.7M | $10.5M | $23.9M | $33.6M |
| Tangible book value | $23.9M | $30.5M | $9.8M | $24.3M | $17.0M | $5.0M | $5.4M | −$3.6M | −$8.4M | −$11.3M | $3.2M | −$5.3M |
| Book value per share | $3.32 | $10.96 | $5.30 | $13.05 | $9.18 | $1.97 | $3.17 | — | — | — | — | — |
| Shares outstanding | 7.3M | 2.8M | 1.9M | 1.9M | 1.9M | 2.7M | 1.8M | — | — | — | — | — |
| Current ratio | 7.07 | 10.10 | 3.42 | 5.01 | 3.41 | 1.37 | 1.65 | 0.49 | 0.82 | 2.99 | 17.59 | 14.96 |
| Quick ratio | 7.07 | 10.36 | 3.42 | 4.63 | 3.41 | 1.37 | 1.65 | 0.30 | 0.14 | 1.60 | 13.06 | 12.20 |
| Equity / assets | 88.9% | 91.5% | 76.3% | 82.6% | 73.0% | 38.5% | 38.8% | −40.6% | −96.2% | −66.0% | 14.6% | −13.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed October 16, 2025); data from EODHD.
BCTX financial position
At the end of fiscal 2025 (July 31, 2025), BriaCell Therapeutics had total assets of $29.8 million (up 265.1% from a year earlier), total liabilities of $5.9 million and shareholders' equity of $24.6 million. Its current ratio was 5.01. In the latest quarter (ended April 30, 2026) total assets were $27.1 million and equity $24.1 million.
Related: BCTX income statement, BCTX cash flow statement, BCTX key metrics. See the BCTX stock overview for the latest quote and news.
BCTX balance sheet FAQ
What are BriaCell Therapeutics's total assets?
BriaCell Therapeutics reported total assets of $29.8 million at the end of fiscal 2025 (July 31, 2025), compared with $8.2 million a year earlier.
How much cash does BriaCell Therapeutics have?
BriaCell Therapeutics held $24.6 million in cash and short-term investments at the end of fiscal 2025.
What is BriaCell Therapeutics's book value?
BriaCell Therapeutics's shareholders' equity (book value) was $24.6 million at the end of fiscal 2025, or $13.05 per share.
What is BriaCell Therapeutics's current ratio?
BriaCell Therapeutics had current assets of $27.4 million and current liabilities of $5.5 million, a current ratio of 5.01 (it can cover its short-term obligations).
How much goodwill does BriaCell Therapeutics have?
BriaCell Therapeutics carried $0.3 million of goodwill and intangible assets, 0.9% of total assets, at the end of fiscal 2025.